PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400995
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400995
Liver Disease Treatment market size was valued at USD 22,300.42 Million in 2022, expanding at a CAGR of 6.42% from 2023 to 2030.
Treatment for liver disease refers to medical measures taken to control and lessen illnesses that have an impact on the structure or operation of the liver. Depending on the exact liver ailment, several treatment modalities are used, but they often entail modifying one's lifestyle, taking medications, and in extreme circumstances, undergoing surgery or a liver transplant. Hepatitis, cirrhosis, fatty liver disease, and liver cancer are examples of common liver illnesses. Controlling inflammation, treating symptoms, avoiding consequences, and addressing underlying causes are frequently the objectives of treatment. To improve results and maintain liver function, early diagnosis, and prompt treatments are essential.
Liver Disease Treatment Market Dynamics
The rise in the number of people with liver diseases propelled the market growth
The increased prevalence of liver disorders, the rise in alcohol usage, and poor eating habits are the main factors anticipated to propel growth in the market for therapies for liver diseases. For instance, according to a research report that was published in the Clinical Liver Disease journal in June 2021, chronic liver disease (CLD), which affects nearly 1.5 billion people worldwide, is one of the major causes of sickness and mortality globally. Furthermore, according to research published in June 2021 by the American Association for the Study of Liver Diseases, non-alcoholic fatty liver disease (NAFLD) is the leading cause of hepatic illness, accounting for 59% of cases, followed by hepatitis C (9%), hepatitis B (29%), and alcoholic liver disease (ALD) (2%). Furthermore, a research published in Clinical and Molecular Hepatology in October 2022 predicted that by 2040, the prevalence of non-alcoholic fatty liver disease (NAFLD) will be 55.7% worldwide. As a result, rising liver ailments have fueled the industry as a whole.
Liver Disease Treatment Market- Key Insights
As per the analysis shared by our research analyst, the Global Liver Disease Treatment market is estimated to grow annually at a CAGR of around 6.42% over the forecast period (2023-2030)
The Liver Disease Treatment market is projected to grow at a significant rate due to the rise in the number of people with liver diseases to propel the market growth
Based on Treatment Type segmentation, Antiviral Drugs was predicted to show maximum market share in the year 2022
Based on Disease Type segmentation, Hepatitis was the leading Disease Type in 2022
On the basis of region, North America was the leading revenue generator in 2022
The Global Liver Disease Treatment market is segmented on the basis of Treatment Type, Disease Type, and Region.
The market is divided into categories based on Treatment Type: Immunosuppressants, Antiviral Drugs, Immunoglobulins, Vaccines, Targeted Therapy, Corticosteroids, and Chemotherapy Drugs. Positive effects are being produced on the antiviral drug's sub-segment by the significantly increasing expenditures in the sector, largely because of its numerous advantages. Additionally, rising healthcare costs, increased public awareness, and an increase in the prevalence of hepatitis B and C are other significant aspects anticipated to support market expansion.
The market is divided into categories based on Disease Type: Autoimmune Diseases, Hepatitis, Non-alcoholic Fatty Liver Disease (NAFLD), Genetic Disorders, Cancer, and Others. Due to pharmaceutical mistakes, excessive alcohol intake, autoimmune disorders, viral infections, and nonalcoholic steatohepatitis, the inflammatory status of the liver tissue has significantly worsened during the past several years.
Liver Disease Treatment Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America region is expected to grow. In 2022, the market for Liver Disease Treatments will be dominated by North America. The extensively increasing need for advanced and innovative liver disease therapeutics particularly in China, India, and South Korea is one of the key elements boosting the development of the industry. Also, one of the major factors behind this growth can be the increasing prevalence of NAFLD and hepatitis, lack of expertise, and the poor healthcare infrastructure in the region.
Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. Some of the primary Types used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in January 2023, Topline data from the Phase 2 SEQUOIA clinical research of experimental Fazirsiran for the treatment of liver disease linked to alpha-1 antitrypsin deficiency (AATD-LD) were released by Takeda and Arrowhead Pharmaceuticals Inc.
In June 2023, according to Ipsen, individuals with Alagille syndrome (ALGS) starting at 12 months of age can now treat their cholestatic pruritus with Bylvay® (odevixibat), as to an FDA approval. Bylvay is a once-daily, minimally systemically exposed, locally acting ileal bile acid transport inhibitor (IBATi) with minimum systemic exposure. In the United States and Europe, Bylvay was authorized as the first medication for treating cholestatic pruritus in individuals with progressive familial intrahepatic cholestasis (PFIC) in 2021. For qualifying ALGS patients, Bylvay is instantly available with a prescription.
The scope of this report covers the market by its major segments, which include as follows: